Disclosure of Events or Information

Press Release - Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD

Acquisition of majority ownership control in A1 Biochem Labs India Private Limited, India and A1 Biochem Labs LLC, USA

ANVISA Approval for CuraTeQ Biologics Biosimilars Manufacturing Facility

Incorporation of a new stepdown subsidiary in Indonesia

Completion of transfer of Companys domestic branded generic pharmaceutical formulations products business to Auropharm Limited

Completion of acquisition of Lannett Company LLC, USA

Completion of US FDA Inspection at Auroactive Pharma Private Limite

Acquisition of 26 stake in Swarnaakshu Solar Power Private Limited

Press Release - Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company

Receipt of FTC approval for the acquisition of Lannett business

Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited, Pashamylaram as OAI

Classification of Unit-3 of Eugia Pharma Specialities Limited, Pashamylaram as OAI

Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg

Press Release - Aurobindo Pharma Inaugurates TheraNym - Pioneering Indias Large-Scale Biologics Contract Manufacturing Facility

Classification of Unit-I of Eugia Pharma Specialities Limited, Shameerpet as OAI

Incorporation of a new step-down subsidiary by the name of Arrow Pharma Production SAS

Reappointment of Internal Auditor

Change in Secretarial Auditor

Change in Secretarial Auditor

Outcome of Board Meeting 21.05.2026

Intimation of receipt of Order form the Honble High Court of Telangana, Hyderabad by the promoters of the Company.

CuraTeQ Biologics Receives CDSCO Marketing Authorisation Form CT 23 for Bevqolva Bevacizumab Biosimilar

Classification of Unit-VII of Aurobindo Pharma Limited, Jedcherla as Voluntary Action Indicated VAI

Intimation of resignation of Dr. Sanjay Chaturvedi, CEO of Apitoria

CuraTeQ Biologics Secures Health Canada NOC for Bevqolva Bevacizumab Biosimilar

Change in Senior Management personnel

Press Release - Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg5 mL OTC

Press Release - Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral Liquid,1.1 grams per mL

Expanding Existing CMO Operations with Merck Sharpe Dohme Singapore Trading Pte. Ltd By Theranym Biologics

Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets

Press Release - Aurobindo Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11

Transfer of the Companys domestic branded generic pharmaceutical formulations products business to Auropharm Limited

Outcome of Board Meeting - Buyback

Update on solar power purchase agreement and acquisition upto 26 stake in Swarnaakshu Solar Power Private Limited

Entry into Marketing and Distribution Agreement for Biosimilars in EU Territories by CuraTeQ Biologics Pvt.Ltd

Classification of Unit- V of Apitoria Pharma Private Limited as VAI by the US FDA

Classification of Unit-II of Eugia Pharma Specialities Limited as OAI by the US FDA

Intimation of order received from GST authorities

Classification of Unit-IV of APL Healthcare Limited as VAI by the US FDA

Press Release - Eugia Pharma announces launch of Pomalidomide Capsules in the US

Clarification on media report, Aurobindo Pharmas P Sarath Chandra Reddy acquitted in Delhi Liquor Scam case

Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd.,

Press Release - Eugia Pharma receives USFDA Approval for Everolimus Tablets

Incorporation of Engenra Biologics Private Limited

Intimation of Orders received from CGST, Hyderabad

Clarification on news item appearing in https:www.ndtvprofit.com

Press Release - Acrotech Biopharma Inc., Announces FDA Approval of ADQUEYTM difamilast 1 Ointment

Completion of US FDA Inspection at Unit-VII of Aurobindo Pharma Limited, Jedcherla

Outcome of Board Meeting 09.02.2026

Completion of US FDA Inspection at Unit-III of Eugia Pharma Specialities Limited

Clarification on Significant Volume Movement in Companys Shares

Incorporation of a new wholly owned step-down subsidiary in Philippines

CuraTeQ Biologics receives NOC from Health Canada for its biosimilar Dyrupeg

Acquisition of the branded non-oncology prescription formulations business of Khandelwal Laboratories Pvt.Ltd., by Auro Pharma Limited